Sign in or create an account to add this stock to your watchlist.
About Stereotaxis (OTCMKTS:STXS)
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.
Industry, Sector and Symbol
Industry Electromedical equipment
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$31.14 million
Price / Sales1.51
Cash Flow$0.0865 per share
Price / Cash9.25
Book Value$0.04 per share
Price / Book20.00
EPS (Most Recent Fiscal Year)N/A
Return on Equity-8.52%
Return on Assets9.14%
Stereotaxis (OTCMKTS:STXS) Frequently Asked Questions
What is Stereotaxis' stock symbol?
Stereotaxis trades on the OTCMKTS under the ticker symbol "STXS."
How were Stereotaxis' earnings last quarter?
Stereotaxis (OTCMKTS:STXS) posted its quarterly earnings data on Monday, May, 14th. The medical equipment provider reported $0.01 EPS for the quarter. The medical equipment provider had revenue of $6.97 million for the quarter. Stereotaxis had a negative return on equity of 8.52% and a negative net margin of 18.08%. View Stereotaxis' Earnings History.
When is Stereotaxis' next earnings date?
Who are some of Stereotaxis' key competitors?
Some companies that are related to Stereotaxis include Helius Medical Technologies (HSDT), Fonar (FONR), Second Sight Medical (EYES), Biolife Solutions (BLFS), Zynex (ZYXI), IRIDEX (IRIX), Edap Tms (EDAP), Semler Scientific (SMLR), Viveve Medical (VIVE), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO), Digirad (DRAD), Dynatronics (DYNT), Nexeon MedSystems (NXNN) and Aradigm (ARDM).
Who are Stereotaxis' key executives?
Stereotaxis' management team includes the folowing people:
- Mr. David Leo Fischel CFA, CPA, Chairman & CEO (Age 31)
- Mr. Martin C. Stammer, Chief Financial Officer (Age 38)
- Ms. Karen Witte Duros, Sr. VP, Gen. Counsel, Compliance Officer and Sec. (Age 63)
- Dr. Gery Tomassoni M.D., FHRS, Chief Medical Officer
- Dr. J. David Burkhardt M.D., F.A.C.C., Chief Devel. Advisor
Has Stereotaxis been receiving favorable news coverage?
News stories about STXS stock have been trending somewhat positive on Monday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Stereotaxis earned a daily sentiment score of 0.18 on Accern's scale. They also gave news headlines about the medical equipment provider an impact score of 47.53 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Stereotaxis' major shareholders?
How do I buy shares of Stereotaxis?
Shares of STXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stereotaxis' stock price today?
One share of STXS stock can currently be purchased for approximately $0.80.
How big of a company is Stereotaxis?
Stereotaxis has a market capitalization of $47.14 million and generates $31.14 million in revenue each year. Stereotaxis employs 117 workers across the globe.
How can I contact Stereotaxis?
Stereotaxis' mailing address is 4320 FOREST PARK AVENUE, ST.LOUIS MO, 63108. The medical equipment provider can be reached via phone at 314-678-6100 or via email at [email protected]
MarketBeat Community Rating for Stereotaxis (STXS)MarketBeat's community ratings are surveys of what our community members think about Stereotaxis and other stocks. Vote "Outperform" if you believe STXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Stereotaxis (OTCMKTS:STXS) Analyst Ratings History
(Data available from 5/21/2016 forward)
Stereotaxis (OTCMKTS:STXS) Earnings History and Estimates Chart
Stereotaxis (OTCMKTS STXS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2018|| || || || || || || || |
|5/14/2018||Q1 2018||$0.01||$6.97 million||View||N/A|
|3/6/2018||Q4 2017||($0.01)||$7.56 million||View||Listen|
|11/9/2017||Q3 2017||($0.02)||$8.14 million||View||N/A|
|8/10/2017||Q2 2017||($0.02)||$8.47 million||View||N/A|
|5/8/2017||Q1 2017||$0.01||$6.98 million||View||Listen|
|3/16/2017||Q4 2016||$0.24||$7.31 million||View||N/A|
|11/7/2016||Q3 2016||($0.09)||$8.33 million||View||N/A|
|8/9/2016||Q2 2016||($0.11)||$7.88 million||View||N/A|
|5/9/2016||Q1||($0.11)||$9.50 million||$8.60 million||View||Listen|
|2/22/2016||Q4||($0.10)||$9.80 million||$9.20 million||View||Listen|
|11/3/2015||Q3||($0.05)||$8.90 million||$9.30 million||View||Listen|
|8/4/2015||Q215||($0.12)||$120.60 million||$9.66 million||View||N/A|
|5/6/2015||Q115||($0.15)||$8.40 million||$9.50 million||View||Listen|
|2/25/2015||Q414||$0.04||$9.10 million||$9.80 million||View||Listen|
|11/5/2014||Q3 2014||($0.10)||$8.85 million||View||N/A|
|8/4/2014||Q2 2014||($0.16)||$8.05 million||View||N/A|
|5/6/2014||Q1||($0.16)||$8.40 million||$8.40 million||View||Listen|
|2/25/2014||Q4||($0.19)||$12.20 million||$9.10 million||View||Listen|
|11/12/2013||Q3||($0.26)||$9.70 million||$10.80 million||View||N/A|
|8/8/2013||Q2 2013||($0.59)||($0.37)||$10.80 million||$9.70 million||View||Listen|
|5/13/2013||Q1 2013||($0.50)||($0.61)||$12.00 million||$8.40 million||View||Listen|
|11/5/2012||Q312||($0.72)||($0.33)||$10.30 million||$11.60 million||View||N/A|
Stereotaxis (OTCMKTS:STXS) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Stereotaxis (OTCMKTS STXS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 38.09%
Institutional Ownership Percentage: 2.35%
Stereotaxis (OTCMKTS STXS) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/15/2015||Fred A Middleton||Director||Sell||26,064||$1.57||$40,920.48|| |
|6/12/2015||Fred A Middleton||Director||Sell||16,273||$1.61||$26,199.53|| |
|6/9/2015||Fred A Middleton||Director||Sell||106,876||$1.65||$176,345.40|| |
|3/13/2015||David Benfer||Director||Buy||3,000||$1.95||$5,850.00|| |
|12/12/2014||William C Mills III||CEO||Buy||10,000||$1.45||$14,500.00|| |
|12/9/2014||Fred A Middleton||Director||Sell||8,551||$1.51||$12,912.01|| |
|12/5/2014||William C Mills III||CEO||Buy||10,000||$1.43||$14,300.00|| |
|12/3/2014||Fred A Middleton||Director||Sell||15,809||$1.59||$25,136.31|| |
|8/11/2014||William C Mills III||CEO||Buy||10,000||$2.75||$27,500.00|| |
|3/13/2014||Fred A Middleton||Director||Sell||24,302||$4.21||$102,311.42|| |
|8/23/2013||Fred A Middleton||Director||Sell||14,600||$3.67||$53,582.00|| |
|8/20/2013||Christopher D Alafi||Major Shareholder||Sell||261,241||$3.74||$977,041.34|| |
|8/7/2013||Fred A Middleton||Director||Sell||78,974||$10.13||$800,006.62|| |
|11/30/2012||Fred A Middleton||Director||Buy||24,360||$1.53||$37,270.80|| |
Stereotaxis (OTCMKTS STXS) News Headlines
Stereotaxis (OTCMKTS:STXS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Stereotaxis (OTCMKTS:STXS) Income Statement, Balance Sheet and Cash Flow Statement
Stereotaxis (OTCMKTS STXS) Stock Chart for Monday, May, 21, 2018